ROYAL-COMMISSION-ALULA
19.12.2019 22:23:14 CET | Business Wire | Press release
The second Winter at Tantora Festival in AlUla in North West Saudi Arabia starts today – a three-month celebration that will showcase the very best in international music, art and culture connecting East and West as the AlUla county has done for thousands of years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005781/en/
It comes just months after Saudi Arabia introduced tourist visas to citizens from 49 countries making the Kingdom more accessible than ever with the UNESCO World Heritage site at Hegra in AlUla among those featured in a global marketing campaign.
The festival is part of the Cultural Manifesto that was launched by the festival organisers, the Royal Commission for AlUla, in Paris in October as part of a long-term strategy to transform the region and open the region as a global living museum and place of culture, heritage and the arts.
Winter at Tantora will cover 12 weekends from 19th December and host a wide range of events from the world-famous Dakar Rally; international ballooning festival; the world’s second longest endurance horse race; the world’s first desert polo tournament and welcome pop-up restaurants from globally renowned restaurants.
The spectacular mirrored wall Maraya Theatre with its 500-seat capacity and operatic sound quality will be home throughout the festival to some of the world’s leading performers who range from Omar Khairat to Andrea Bocelli.
Festival visitors will also be able to meet and engage with young members of the AlUla community who are benefitting from a diverse range of training programmes in hospitality; culture; nature and the environment and studying overseas including 24 men and women at the FERRANDI Paris culinary institute in Paris.
These young chefs will work alongside Michelin-starred experts during the festival creating world-class cuisine that will incorporate local ingredients from the fertile AlUla valley and blending traditional recipes with modern cuisine.
RCU CEO Amr AlMadani says: “Festival visitors will be given a unique opportunity to visit and experience one of the world’s undiscovered places and its spectacular heritage sites before we reopen them to the world in October 2020.
“They will get a tantalising glimpse of a place that been a cultural crossroads for thousands of years and the chance to see it from the serenity of a hot air balloon; the adrenaline of soaring over the desert and mountains in an open seater biplane or exploring hidden canyons in traditional vintage Land Rovers.”
The Royal Commission for AlUla has also completed major infrastructure work at AlUla airport – increasing capacity fourfold to 400,000 visitors a year and upgrading local mountain resorts to enhance the visitor experience.
AlUla will be a worldwide destination for those seeking a unique experience of the full meaning and context of landscape – an experience that integrates the natural and cultural heritage as one living environment. By safeguarding our precious landscapes and cultural heritage this open-air museum will be the Kingdom’s gift to the world creating remarkable and lasting memories.
‘Authentic AlUla’, the opening weekend, is a celebration rooted in AlUla, to mark the start of the winter planting season at the iconic Tantora sundial from which the festival is named. It is the first of 12 specially themed weekends.
Notes to editors
To find out more about the Winter at Tantora festival and details of packages and the entertainment and cultural programmes, log on to www.experiencealula.com
To find out more about how the Royal Commission for AlUla is working with the community to develop a world-class tourism destination, log on to www.rcu.gov.sa
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005781/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom